



A Leader in Pharmaceutical, Biotechnology and Medical Device R&D Outsourcing

Dedicated to Superior Service


With operations in both China and the U.S., WuXi PharmaTech is a leading provider of laboratory and manufacturing services to pharmaceutical, biotechnology, and medical device companies. In our 12-year history, we have established strong relationships with the world's leading healthcare manufacturers, including the largest pharmaceutical companies.

WuXi has proven it can improve R&D productivity by shortening drug-development times and delivering the highest-quality services. We work with our customers to provide them with the capabilities and capacity they need throughout the drug-delivery process, from bench to market. Recognizing the value we bring, these customers have rewarded us with new, larger, and longer contracts and numerous awards.

WuXi's commitment to broadening its service platform has resulted in strong revenue growth throughout its history. We expect continued strong revenue growth, particularly from integrated drug discovery services, small-molecule drug development and manufacturing, biologics services, and clinical research services.

Financial results reflect strong, broad-based, long-term revenue and earnings growth

(US\$ in millions, except per-share)



* Reflects activity relating to proposed Charles River Laboratories transaction

Condensed Consolidated Statements of Operations

(US\$ in millions, except per-share)	1H13	1H12	% Change
Laboratory Services Net Revenues	203.4	180.2	13%
Manufacturing Services Net Revenues	70.8	68.2	4%
Total Net Revenues	274.2	248.4	10%
Laboratory Services Gross Profit	77.8	66.5	17%
Manufacturing Services Gross Profit	21.4	21.9	(2%)
Total Gross Profit	99.2	88.4	12%
Operating Expenses	(50.5)	(44.0)	15%
Operating Income	48.7	44.4	10%
Other Income/Expenses	12.2	5.3	131%
Income Before Income Taxes	60.9	49.7	23%
Income Tax Expenses	(9.6)	(8.2)	17%
Net Income	51.3	41.5	24%
Diluted Earnings per ADS	.71	.56	27%

WuXi PharmaTech Value Proposition

- Experienced international management
- Highly educated and trained workforce
- Broad technical expertise
- Operational excellence
- World-class facilities in China and the U.S.
- Broad platform of integrated laboratory and manufacturing services
- Reputation for reliably delivering high-quality, cost-effective services
- Strong relationships with the world's largest pharmaceutical companies and other leading healthcare manufacturers
- Flexible contractual arrangements
- Strict intellectual-property protection

2013 Goals Position WuXi for Future Growth

- Continued revenue growth across China-based Laboratory Services, driven by our ability to deliver high-quality services and drug candidates for our customers
- Increasing utilization of our integrated drug development services for API manufacturing, IND-enabling toxicology studies and IND filings with the China SFDA and global regulatory authorities
- Continuing growth in Manufacturing Services driven by a growing late-stage product pipeline
- Ramp-up of biologics drug discovery, development, and manufacturing services
- Expansion of our clinical development platform

WuXi's Service Offerings

China-Based Laboratory Services

- Synthetic chemistry
- Medicinal chemistry
- Discovery biology
- DMPK/ADME
- Formulation development
- Toxicology
- Biologics discovery and development
- Biologic reagents
- Clinical development
- Bioanalytical services
- Analytical/stability testing
- Genomics

U.S.-Based Laboratory Services

- Medical device safety testing
- Biologic products safety testing
- Tissue processing services
- Cell banking
- Cell therapy
- Microbiology testing
- Lot release testing

Manufacturing Services

- Process chemistry
- API manufacturing
- Advanced intermediates manufacturing
- Process scale-up
- Process validation
- Biologics manufacturing (monoclonal antibodies, therapeutic proteins)

Investment Profile

Market cap	\$1.7 Billion
Current price	\$23.68
52 week high	\$24.95
52 week low	\$13.54
ADS outstanding	72.5 M

Price as of August 16, 2013
Source: NYSE, Bloomberg

With High Customer Retention

>1,600 customers, including **virtually all of the world's largest** pharmaceutical companies by revenue.

100% repeat business from top 10 customers over last three years.

Contact Details

Ronald Aldridge
Director, Investor Relations
WuXi AppTec
+1-201-585-2048
Ron_Aldridge@wuxiapptec.com or
ir@wuxiapptec.com

This Fact Sheet contains forward-looking statements. Please refer to our latest filings on www.sec.gov for complete description of all risks that may affect our expectations. The Fact Sheet is accurate only as of the date it is printed: August 16, 2013.